Page 1

Summit therapeutics Summit Therapeutics Inc. ( " We , ' ' Summit , ' or the ' Company ' ) Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31 , 2021 Cambridge , MA , May 17 , 2021 - Summit Therapeutics Inc. ( NASDAQ : SMMT ) today reports its financial results and provides an update on its operational progress for the first quarter ended March 31 , 2021 . Note : A glossary of terms is included at the end of this document in order to allow for the ease of understanding of terms or concepts in advance of reviewing this release . Ridinilazole for C. difficile Infection ( ' CDI ' ) 1 . As of May 14 , 2021 , Summit had enrolled a total of 652 patients into its two ridinilazole Phase 3 Ri - CODIFY clinical trials ; together , both trials have a projected enrollment goal of 1,360 patients . Below is a table outlining the enrollment statistics by calendar quarter since the opening of the trials in February 2019 . Quarter Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 * Number of Patients Enrolled 9 21 43 78 101 73 64 105 109 49 * Cumulative Patients Enrolled 9 30 73 151 252 325 389 494 603 652 * 2 . 3 . 4 . 5 . * Q2 2021 includes quarter - to - date enrollment through May 14 , 2021 As previously disclosed , Summit is not providing public commentary on the timing of completion of the Phase 3 Ri - CODIFY clinical trials . The Company plans to publicly update stakeholders quarterly as to enrollment status . The Ri - CoDIFY clinical trials aim to support application for marketing approval of the precision antibiotic ridinilazole in the United States and other territories , with the goal of use as first - line therapy to treat initial infection and reduce recurrence of CDI . BARDA is supporting the Phase 3 clinical trials and regulatory development of ridinilazole with a financial award of potential funding of up to $ 72.5 million . As of March 31 , 2021 , an aggregate of $ 53.9 million had been received . As presented within the American Journal of Physiology - Gastrointestinal and Liver Physiology ( August 2020 ) , dysbiosis of the gut microbiota with altered bile acid composition within the microbiome is believed to play a critical role in C. difficile infection , including recurrence of disease . Ridinilazole has , thus far , shown a significant relative sparing of the microbiome compared to the broad - spectrum antibiotics that are the current standard of care for C. diff infection treatment today .